A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Mosunetuzumab (Primary) ; Tocilizumab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 03 Jul 2019 Planned End Date changed from 3 Oct 2023 to 19 Apr 2023.
- 03 Jul 2019 Planned primary completion date changed from 3 Oct 2023 to 19 Apr 2023.
- 02 May 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Mar 2019 to 31 May 2019.